{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:32:55Z","timestamp":1793039575717,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-026-03068-2","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:38:04Z","timestamp":1775090284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and determinants of polypharmacy among cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Mohamed M.","family":"Tawengi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Al Shibly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-5278","authenticated-orcid":false,"given":"Mohammed I.","family":"Danjuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"3","key":"3068_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443\u201352.","journal-title":"Eur Geriatr Med"},{"key":"3068_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042098620933741","volume":"11","author":"M Khezrian","year":"2020","unstructured":"Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:1\u201310.","journal-title":"Ther Adv Drug Saf"},{"key":"3068_CR3","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"3068_CR4","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from: www.cochrane.org\/handbook."},{"key":"3068_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2021.01.012","volume":"134","author":"JC Stone","year":"2021","unstructured":"Stone JC, Glass K, Clark J, Ritskes-Hoitinga M, Munn Z, Tugwell P, et al. The MethodologicAl STandards for Epidemiological Research (MASTER) scale demonstrated a unified framework for bias assessment. J Clin Epidemiol. 2021;134:52\u201364.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"3068_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods"},{"key":"3068_CR7","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. Available from: https:\/\/www.bmj.com\/content\/327\/7414\/557.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"3068_CR8","doi-asserted-by":"crossref","unstructured":"Quintana DS. From pre-registration to publication: a non-technical primer for conducting a meta-analysis to synthesize correlational data. Front Psychol. 2015;6:1549. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26500598.","DOI":"10.3389\/fpsyg.2015.01549"},{"issue":"4","key":"3068_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195\u2013203.","journal-title":"Int J Evid Based Healthc"},{"key":"3068_CR10","doi-asserted-by":"crossref","unstructured":"Kre\u010dak I, Pivac L, Lucijani\u0107 M, Skelin M. Polypharmacy, potentially inappropriate medications, and drug-to-drug interactions in patients with chronic myeloproliferative neoplasms. Biomedicines. 2023;11(5):1301","DOI":"10.3390\/biomedicines11051301"},{"issue":"1","key":"3068_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jgo.2017.07.015","volume":"9","author":"DY Leger","year":"2018","unstructured":"Leger DY, Moreau S, Signol N, Fargeas JB, Picat MA, Penot A, et al. Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: observational single-center study of 122 patients. J Geriatr Oncol. 2018;9(1):60\u20137. https:\/\/doi.org\/10.1016\/j.jgo.2017.07.015.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"3068_CR12","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12877-022-03390-z","volume":"22","author":"I Ortland","year":"2022","unstructured":"Ortland I, Mendel Ott M, Kowar M, Sippel C, Ko YD, Jacobs AH, et al. Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity. BMC Geriatr. 2022;22(1):716.","journal-title":"BMC Geriatr"},{"issue":"6","key":"3068_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s11096-019-00910-7","volume":"41","author":"M Castro-Manzanares","year":"2019","unstructured":"Castro-Manzanares M, do Pazo-Oubi\u00f1a F, Rodr\u00edguez-Rinc\u00f3n RM. Prevalence of potential drug\u2013drug interactions in outpatients on treatment with parenteral antineoplastic drugs. Int J Clin Pharm. 2019;41(6):1429\u201333.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"3068_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jgo.2018.02.007","volume":"9","author":"E Ramsdale","year":"2018","unstructured":"Ramsdale E, Lemelman T, Loh KP, Flannery M, Kehoe L, Mullaney T, et al. Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers. J Geriatr Oncol. 2018;9(5):534\u20139.","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"3068_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jgo.2021.02.021","volume":"12","author":"AH Lavan","year":"2021","unstructured":"Lavan AH, O\u2019Mahony D, O\u2019Mahony D, Gallagher P. Potentially inappropriate medication (PIM) use and severe drug interactions (SDIs) in older adults with cancer. J Geriatr Oncol. 2021;12(6):872\u201380.","journal-title":"J Geriatr Oncol"},{"key":"3068_CR16","doi-asserted-by":"crossref","unstructured":"van Loveren FMAM, van Berlo - van de Laar IRF, Imholz ALT, van \u2019t Riet E, Taxis K, Jansman FGA. Prevalence and follow-up of potentially inappropriate medication and potentially omitted medication in older patients with cancer \u2013 The PIM POM study. J Geriatr Oncol. 2021;12(1):80\u20134.","DOI":"10.1016\/j.jgo.2020.06.014"},{"issue":"1","key":"3068_CR17","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","volume":"25","author":"MR Mohamed","year":"2020","unstructured":"Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, et al. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist. 2020;25(1):e94\u2013108. https:\/\/doi.org\/10.1634\/theoncologist.2019-0406.","journal-title":"Oncologist"},{"issue":"4","key":"3068_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s11764-021-01161-0","volume":"17","author":"AC Betts","year":"2023","unstructured":"Betts AC, Murphy CC, Shay LA, Balasubramanian BA, Markham C, Allicock M. Polypharmacy and prescription medication use in a population-based sample of adolescent and young adult cancer survivors. J Cancer Surviv. 2023;17(4):1149\u201360.","journal-title":"J Cancer Surviv"},{"issue":"3","key":"3068_CR19","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1634\/theoncologist.2019-0085","volume":"25","author":"S Hong","year":"2020","unstructured":"Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, et al. Polypharmacy, inappropriate medication use, and drug interactions in older korean patients with cancer receiving first-line palliative chemotherapy. Oncologist. 2020;25(3):e502\u201311.","journal-title":"Oncologist"},{"key":"3068_CR20","doi-asserted-by":"crossref","unstructured":"AA Laban, N Birand, U Chukwunyere1, A Abdi BB. Evaluation of drug\u2011drug interactions in cancer patients treated at a University Hospital in North Cyprus using two interaction databases. Niger J Clin Pract. 2021;24(7):1067\u201371.","DOI":"10.4103\/njcp.njcp_266_20"},{"issue":"1","key":"3068_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-10939-7","volume":"23","author":"H Pluchart","year":"2023","unstructured":"Pluchart H, Bailly S, Chanoine S, Moro-Sibilot D, Bedouch P, Toffart AC. Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients. BMC Cancer. 2023;23(1):1\u20136.","journal-title":"BMC Cancer"},{"issue":"1","key":"3068_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/1055-9965.EPI-17-0523","volume":"27","author":"JL Lund","year":"2018","unstructured":"Lund JL, Sanoff HK, Hinton SP, Muss HB, Pate V, St\u00fcrmer T. Potential medication-related problems in older breast, colon, and lung cancer patients in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(1):41\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"3068_CR23","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00432-020-03252-4","volume":"146","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki T, Hosomi Y, Shimizu A, Kitadai R, Mirokuji K, Okuma Y. Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1\/PD-L1 antibody-based immunotherapy. J Cancer Res Clin Oncol. 2020;146(10):2659\u201368.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"3068_CR24","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1016\/j.jgo.2024.101832","volume":"15","author":"N Morikawa","year":"2024","unstructured":"Morikawa N, Naito T, Morita M, Sekikawa M, Doshita K, Yabe M, et al. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors: a retrospective cohort study. J Geriatr Oncol. 2024;15(7):101832.","journal-title":"J Geriatr Oncol"},{"issue":"17","key":"3068_CR25","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1002\/cncr.34813","volume":"129","author":"DW Choi","year":"2023","unstructured":"Choi DW, Kang H, Zhang HS, Jhang H, Jeong W, Park S. Association of polypharmacy with all-cause mortality and adverse events among elderly colorectal cancer survivors. Cancer. 2023;129(17):2705\u201316.","journal-title":"Cancer"},{"issue":"7","key":"3068_CR26","doi-asserted-by":"publisher","first-page":"E580","DOI":"10.1093\/oncolo\/oyac053","volume":"27","author":"E Ramsdale","year":"2022","unstructured":"Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, et al. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancertreatment. Oncologist. 2022;27(7):E580\u20138.","journal-title":"Oncologist"},{"issue":"9","key":"3068_CR27","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","volume":"24","author":"AH Lavan","year":"2019","unstructured":"Lavan AH, O\u2019Mahony D, Buckley M, O\u2019Mahony D, Gallagher P. Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. Oncologist. 2019;24(9):e968\u201377.","journal-title":"Oncologist"},{"issue":"1","key":"3068_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jgo.2020.09.011","volume":"12","author":"T Hakozaki","year":"2021","unstructured":"Hakozaki T, Matsuo T, Shimizu A, Ishihara Y, Hosomi Y. Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors. J Geriatr Oncol. 2021;12(1):64\u201371.","journal-title":"J Geriatr Oncol"},{"key":"3068_CR29","doi-asserted-by":"crossref","unstructured":"Escudero-Vilaplana V, Collado-Borrell R, Hoyo-Mu\u00f1oz A, Gimenez-Manzorro A, Calles A, Osorio S, et al. Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. Expert Opin Drug Saf. 2020;19:1041\u20131048.","DOI":"10.1080\/14740338.2020.1781089"},{"key":"3068_CR30","doi-asserted-by":"publisher","unstructured":"Kurisu K, Miyabe D, Furukawa Y, Shibayama O, Yoshiuchi K. Association between polypharmacy and the persistence of delirium: a retrospective cohort study Abstract BioPsychoSocial Medicine. 2020;14(1). https:\/\/doi.org\/10.1186\/s13030-020-00199-3.","DOI":"10.1186\/s13030-020-00199-3"},{"key":"3068_CR31","doi-asserted-by":"publisher","unstructured":"Ham L, Geijteman ECT, Aarts MJ, Kuiper JG, Kunst PWA, Raijmakers NJH, et al. Use of potentially inappropriate medication in older patients with lung cancer at the end of life. J Geriatr Oncol. 2022;13(1):53\u20139. https:\/\/doi.org\/10.1016\/j.jgo.2021.07.009.","DOI":"10.1016\/j.jgo.2021.07.009"},{"key":"3068_CR32","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (Version 5.1.0). The Cochrane Collaboration; 2011."},{"issue":"3","key":"3068_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/fampra\/17.3.261","volume":"17","author":"L Veehof","year":"2000","unstructured":"Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17(3):261\u20137.","journal-title":"Fam Pract"},{"key":"3068_CR34","doi-asserted-by":"crossref","unstructured":"Danjuma MIMU, Naseralallah L, Ansari S, Al Shebly R, Elhams M, Alshamari M, et al. Prevalence and global trends of polypharmacy in patients with chronic liver disease: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(19):32608","DOI":"10.1097\/MD.0000000000032608"},{"key":"3068_CR35","doi-asserted-by":"crossref","unstructured":"Mohammed I. Danjuma , Oyelola A. Adegboye, Ahmed Aboughalia NS, Ruba Almishal, Haseeb Abdul, Mohamad Faisal Hamad Mohamed MNE, Abdulatif AlKhal, Abdelnaser Elzouki, Arwa Al-Saud MC, Bidmos and MA. Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis. Ther Adv Drug Saf. 2022 Aug 23;13:20420986221080795","DOI":"10.1177\/20420986221080795"},{"key":"3068_CR36","doi-asserted-by":"crossref","unstructured":"Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022; 27(2): 465-492.","DOI":"10.1007\/s10741-021-10135-4"},{"key":"3068_CR37","doi-asserted-by":"crossref","unstructured":"Chen LJ, Trares K, Laetsch DC, Nguyen TNM, Brenner H, Sch\u00f6ttker B. Systematic review and meta-analysis on theassociations of polypharmacy and potentially inappropriate medication with adverse outcomes in older cancer patients. J Gerontol A Biol Sci Med Sci. 2021;76.","DOI":"10.1093\/gerona\/glaa128"},{"key":"3068_CR38","doi-asserted-by":"crossref","unstructured":"Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, Hughes CM. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5(12):e009235.","DOI":"10.1136\/bmjopen-2015-009235"},{"issue":"7","key":"3068_CR39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jcpt.13633","volume":"47","author":"A El-Awaisi","year":"2022","unstructured":"El-Awaisi A, Al-Shaibi S, Al-Ansari R, Naseralallah L, Awaisu A. A systematic review on the impact of pharmacist-provided services on patients\u2019 health outcomes in Arab countries. J Clin Pharm Ther. 2022;47(7):879\u201396.","journal-title":"J Clin Pharm Ther"},{"key":"3068_CR40","doi-asserted-by":"crossref","unstructured":"Isleem N, Shoshaa S, AbuGhalyoun A, Khatib M, Naseralallah LM, Ibn-Mas\u2019ud Danjuma M, et al. Critical care tele-pharmacy services during COVID-19 pandemic: a qualitative exploration of healthcare practitioners\u2019 perceptions. J Clin Pharm Ther. 2022;47(10):1591\u20139.","DOI":"10.1111\/jcpt.13709"},{"issue":"1","key":"3068_CR41","first-page":"1","volume":"11","author":"SH Steinmo","year":"2016","unstructured":"Steinmo SH, Michie S, Fuller C, Stanley S, Stapleton C, Stone SP. Bridging the gap between pragmatic intervention design and theory: using behavioural science tools to modify an existing quality improvement programme to implement \u201cSepsis Six.\u201d Implement Sci. 2016;11(1):1\u201312.","journal-title":"Implement Sci"},{"issue":"1","key":"3068_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/qshc.2004.011155","volume":"14","author":"S Michie","year":"2005","unstructured":"Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making psychological theory useful for implementing evidence based practice: a consensus approach. Qual Saf Health Care. 2005;14(1):26\u201333.","journal-title":"Qual Saf Health Care"},{"issue":"3","key":"3068_CR43","first-page":"601","volume":"38","author":"CM Hughes","year":"2016","unstructured":"Hughes CM, Cadogan CA, Ryan CA. Development of a pharmacy practice intervention: lessons from the literature. Int J Clin Pharm. 2016;38(3):601\u20136.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"3068_CR44","first-page":"71","volume":"23","author":"J Lindsay","year":"2015","unstructured":"Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, et al. The development and evaluation of an oncological palliative care deprescribing guideline: the \u201cOncPal deprescribing guideline.\u201d Support care cancer Off J Multinatl Assoc Support Care Cancer. 2015;23(1):71\u20138.","journal-title":"Support care cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"3068_CR45","unstructured":"Duerden Martin, Avery Tony PR. Polypharmacy and medicines optimisation Making it safe and sound. The King\u2019s Fund; 2013."},{"issue":"2","key":"3068_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4143\/crt.2025.264","volume":"57","author":"EH Park","year":"2025","unstructured":"Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022. Cancer Res Treat. 2025;57(2):312\u201330.","journal-title":"Cancer Res Treat"},{"key":"3068_CR47","unstructured":"Mair A, Fernandes-Llimos F, Alonso A, Harrison C, Hurding S, Kempen T, Kinnear M, Michael N, Mcintosh J, Wilson M. Polypharmacy management by 2030: a patient safety challenge. Simpathy Consortium; 2017."},{"issue":"34","key":"3068_CR48","doi-asserted-by":"publisher","first-page":"e34818","DOI":"10.1097\/MD.0000000000034818","volume":"102","author":"JY Dong","year":"2023","unstructured":"Dong JY, Ju JH, Yang YM. Analysis of the prescription trends of potentially inappropriate medications in Korean older outpatients by sex: a retrospective study using data from the health insurance review and assessment service. Medicine (Baltimore). 2023;102(34):e34818.","journal-title":"Medicine (Baltimore)"},{"key":"3068_CR49","doi-asserted-by":"crossref","unstructured":"Ismail M, Noor S, Harram U, Haq I, Haider I, Khadim F, et al. Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study. BMC Health Serv Res. 2018 t;18(1):762.","DOI":"10.1186\/s12913-018-3579-7"},{"issue":"4","key":"3068_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/jrpp.jrpp_40_24","volume":"12","author":"T Gholipourshahraki","year":"2023","unstructured":"Gholipourshahraki T, Aria A, Sharifi M, Moghadas A, Moghaddas A. Potential drug interactions in hospitalized hematologic cancer patients: new update with new chemotherapy regimens. J Res Pharm Pract. 2023;12(4):115\u201322.","journal-title":"J Res Pharm Pract"},{"issue":"1","key":"3068_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12877-024-05135-6","volume":"24","author":"RF Oliveira","year":"2024","unstructured":"Oliveira RF, Oliveira AI, Cruz AS, Ribeiro O, Afreixo V, Pimentel F. Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors. BMC Geriatr. 2024;24(1):557.","journal-title":"BMC Geriatr"},{"key":"3068_CR52","doi-asserted-by":"publisher","unstructured":"Mohamed M Tawengi, Jawaher Baraka, Rafal Al Shebly et al. Prevalence and global factors influencing polypharmacy and its clinical phenotypes in cancer patients: a systematic review and meta-analysis, 08 August 2025, PREPRINT (Version 1) available at Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-6896596\/v1.","DOI":"10.21203\/rs.3.rs-6896596\/v1"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03068-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:00:52Z","timestamp":1783735252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3068"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03068-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6896596\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: authors would like to update the Funding and Acknowledgement statements of the article","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}